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he Akt family of kinases are activated by growth
factors and regulate pleiotropic cellular activities. In
this study, we provide evidence for isoform-speciﬁc
positive and negative roles for Akt1 and -2 in regulating
growth factor–stimulated phenotypes in breast epithelial
cells. Insulin-like growth factor-I receptor (IGF-IR) hyper-
stimulation induced hyperproliferation and antiapoptotic
activities that were reversed by Akt2 down-regulation. In
contrast, Akt1 down-regulation in IGF-IR–stimulated cells
promoted dramatic neomorphic effects characteristic of an
epithelial–mesenchymal transition (EMT) and enhanced
cell migration induced by IGF-I or EGF stimulation. The
T
 
phenotypic effects of Akt1 down-regulation were accom-
panied by enhanced extracellular signal–related kinase
(ERK) activation, which contributed to the induction of mi-
gration and EMT. Interestingly, down-regulation of Akt2
suppressed the EMT-like morphological conversion in-
duced by Akt1 down-regulation in IGF-IR–overexpressing
cells and inhibited migration in EGF-stimulated cells.
These results highlight the distinct functions of Akt iso-
forms in regulating growth factor–stimulated EMT and
cell migration, as well as the importance of Akt1 in cross-
regulating the ERK signaling pathway.
 
Introduction
 
The Akt/PKB family of kinases, Akt1, -2, and -3, plays critical
roles in regulating growth, proliferation, survival, metabolism,
and other cellular activities. Akt kinases control these activities
by phosphorylation-mediated regulation of multiple substrates
(for reviews see Brazil et al., 2004; Woodgett, 2005). Deregu-
lated, or enhanced, Akt signaling has also been implicated in a
variety of human cancers, and may promote tumorigenesis (for
review see Bellacosa et al., 2005). However, the specific con-
tribution of Akt isoforms to phenotypes in normal and cancerous
cells have not been clearly elucidated.
Akt activity is induced by ligand stimulation of growth
factor receptors, such as the insulin-like growth factor-I receptor
(IGF-IR) and the EGF family of receptors. Both IGF-I and
EGF receptor signaling lead to pleiotropic effects in normal
and cancerous cells (for reviews see Hynes and Lane, 2005;
Foulstone et al., 2005). Multiple signaling proteins are activated
downstream of these receptors, including the extracellular sig-
nal–related kinase (ERK)/MAP kinase, phosphatidyl-inositol-3
 
 
 
(PI 3) kinase, and AKT. Ligand stimulation activates PI 3-kinase,
the upstream activator of Akt, by direct binding of PI 3-kinase
subunits to either the activated, phosphorylated receptor or to
adaptor proteins phosphorylated by receptor kinase activity
(Yamamoto et al., 1992; Myers et al., 1993). Phosphoinositides
generated by PI 3-kinase activity trigger activation of Akt ki-
nases through direct binding to the pleckstrin homology (PH)
domain and the subsequent phosphorylation of Akt at two con-
served residues (for review see Woodgett, 2005).
Although the three Akt isoforms are structurally homolo-
gous and share similar mechanisms of activation, they also ex-
hibit distinct features. Akt1 and -2 are ubiquitously expressed,
whereas Akt3 has been reported to have a more limited tissue
distribution (Yang et al., 2003). Emerging evidence supports
distinct functions for Akt isoforms in normal cells, as well as in
tumor cells. Studies of Akt isoform deficient mice highlight the
potentially nonredundant functions of Akt1 and -2. 
 
Akt1
 
 
 
/
 
 
 
 mice
are small with significant growth defects, and 
 
Akt2
 
 
 
/
 
 
 
 mice are
unable to maintain glucose homeostasis (Cho et al., 2001a,b).
Akt2 was also implicated in insulin-stimulated glucose metabo-
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lism by studies using 
 
Akt2
 
 
 
/
 
 
 
 mouse embryo fibroblasts or 3T3-
LI adipocytes transfected with isoform-specific short interfering
RNA (Bae et al., 2003; Jiang et al., 2003; Katome et al., 2003).
The loss or down-regulation of Akt2 impairs glycogen synthase
kinase 3
 
 
 
 phosphorylation and glucose transporter 4 translocation
more significantly than Akt1 down-regulation. However, there is
redundancy in function, as the combined down-regulation of
Akt1 and -2 results in more severe defects.
All Akt isoforms possess in vitro transformational ability
(Mende et al., 2001); however, there may be isoform-specific
functions in tumor cells. Akt2 amplification or mutations have
been detected in breast, ovarian, and colon tumors (Bellacosa et
al., 1995; Parsons et al., 2005), whereas Akt1 amplification has
been reported only in a single gastric cancer cell line (Staal, 1987).
Thus, Akt2 may exert isoform-specific effects on tumor progres-
sion. Overexpression of wild-type Akt2, but not Akt1, in an
ErbB2-overexpressing breast cancer cell line enhanced invasive-
ness in vitro and metastases in animal models (Arboleda et al.,
2003). In other studies, overexpression of activated Akt1 in ErbB2
transgenic mouse mammary tumors decreased their metastatic po-
tential but enhanced their proliferation (Hutchinson et al., 2004).
In this paper, we describe surprising isoform-specific
functions of Akt revealed by investigations of the role of Akt
signaling downstream of the IGF-IR. These studies used a non-
transformed breast epithelial cell line, MCF-10A, which displays
a stable epithelial morphology in monolayer culture and forms
hollow, growth-arrested structures in three-dimensional (3D) cul-
tures (Debnath et al., 2003a). IGF-IR hyperstimulation led to the
formation of hyperproliferative 3D structures lacking a hollow
lumen caused by the suppression of apoptosis. Initial studies us-
ing receptor variants indicated that Akt signaling may be critical
for the antiapoptotic and proliferative activities induced by
IGF-IR hyperstimulation, as the substitution of tyrosine residue
950 impaired these phenotypes and inhibited Akt activation, but
not ERK signaling. To investigate the role of Akt in this system,
we examined the consequences of down-regulating expression of
two distinct isoforms, Akt1 and -2, on IGF-I–stimulated pheno-
types. Akt2 down-regulation reverted all aspects of IGF-IR–
induced phenotypic changes in 3D acinar structures. Unexpect-
edly, we found that the specific down-regulation of Akt1 induced
a dramatic phenotype resembling an epithelial–mesenchymal
transition (EMT) and enhanced growth factor–stimulated migra-
tion. These phenotypic changes were associated with up-regula-
tion of ERK/MAPK signaling. Interestingly, Akt2 expression was
required for EMT-like morphological changes induced by Akt1
down-regulation. Our studies suggest that there are isoform-spe-
cific, positive and negative effects of Akt isoforms on migration
and EMT. Furthermore, these distinct effects may result from iso-
form-specific cross-regulation of other signaling pathways.
 
Results
 
Enhanced IGF-I signaling disrupts normal 
mammary acinar architecture and 
morphogenesis
 
To examine the effects of enhanced IGF-I stimulation on mam-
mary acinar architecture, MCF-10A cells overexpressing IGF-IR
cells were generated using a retroviral vector encoding the hu-
man IGF-IR complementary DNA. MCF-10A is an immortal-
ized breast epithelial cell line that has been reported to express
IGF-IR (Tannheimer et al., 1998); however, levels of endoge-
nous receptor were barely detectable by Western blotting (Fig.
1 A). Despite significant overexpression, activation of the re-
ceptor remained ligand dependent (Fig. 1 A). In monolayer cul-
tures, IGF-I stimulation of IGF-IR cells induced a subtle, but
recognizable, conversion from a cuboidal, epithelial morphol-
ogy to a more spindle-shaped morphology (unpublished data).
In 3D basement membrane Matrigel cultures, both IGF-IR
cells and MCF-10A cells overexpressing vector control (Neo
cells) were able to initiate morphogenesis only in the presence
of IGF-I (Fig. 1 B). The inability of vector control cells to form
acini in the absence of ligand suggests a critical role for IGF-I
stimulation in normal acinar morphogenesis. With ligand addi-
tion, IGF-IR cells formed complex structures that were signifi-
cantly larger than control acini. These differences were apparent
as early as day 6 in 3D culture and were sustained throughout
the duration of the assay (Fig. 1 B). This phenotype was depen-
dent on IGF-IR kinase activity, as comparable overexpression
of a kinase-inactive receptor failed to induce the formation of
these large, abnormal structures (unpublished data).
As an initial approach to define pathways that are critical
for changes in acinar structure mediated by enhanced IGF-I
signaling, we examined the effects of overexpressing variants
of IGF-IR with amino acid substitutions at key regulatory sites
outside of the catalytic domain that have been implicated
Figure 1. IGF-IR hyperstimulation induces morphological changes in
mammary epithelial cells. (A) MCF-10A cells overexpressing human IGF-IR
or vector control (Neo) were grown in monolayer cultures containing EGF  
IGF (100 ng/ml). Lysates were immunoblotted with antibody against phos-
phorylated IGF-IR or total receptor. (B) Phase-contrast images of IGF-IR or
Neo cells grown in 3D Matrigel cultures for 16 d in media containing 2%
horse serum and EGF   IGF-I (100 ng/ml). B (C) IGF-IR, Neo, or MCF-
10A cells overexpressing a variant IGF-IR (Y950F) were grown in 3D
Matrigel cultures for 7 or 16 d in 2% horse serum, EGF, and 100 ng/ml
IGF-I. (D) Lysates of IGF-IR, Neo, or Y950F cells grown in monolayer cul-
tures in 2% horse serum, EGF, and 100 ng/ml IGF-I were immunoblotted
with antibody against phosphorylated Akt or phosphorylated, activated
ERK. Bars, 50  M. 
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in IGF-IR signaling (Y1250/1251F, H1293F, 
 
 
 
1280–1283,
K1294L, and Y950F). Y950F was the only variant that was de-
fective in formation of the hyperproliferative 3D structures; it
induced structures that were slightly larger, but otherwise in-
distinguishable, from parental MCF-10A structures (Fig. 1 C
and not depicted). Y950 serves as a binding site for Shc and the
IRS family of adaptor proteins that are critical in the activation
of downstream signaling proteins such as ERK, PI 3-kinase,
and Akt (Craparo et al., 1995). MCF-10A cells overexpressing
the Y950F variant were severely impaired in activation of Akt,
but not ERK, when compared with cells overexpressing wild-
type IGF-IR (Fig. 1 D). The lack of effect on ERK activation is
consistent with a study reporting the importance of other resi-
dues (Y1250/Y1251) in modulating ERK (Leahy et al., 2004).
These studies indicate that IGF-IR Y950 is critical for full Akt
activation and that Akt may be critical for IGF-IR–induced
phenotypic changes.
 
Differential effects of Akt 
isoform-specific down-regulation in 
IGF-IR–overexpressing cells
 
To investigate whether specific Akt isoforms are critical for the
phenotypes induced by IGF-IR in the 3D culture model, we
used RNA interference to specifically down-regulate the ex-
pression of Akt isoforms. Quantitative analyses using purified
Akt1, -2, and -3 as protein standards revealed that Akt1 is
present in excess of Akt2 (approximately threefold) and -3
(slightly less than twofold; Fig. S1, available at http://www.
jcb.org/cgi/content/full/jcb.200505087/DC1). Retroviral or
lentiviral vectors encoding short hairpin RNA (shRNA) se-
quences were used to specifically down-regulate the expression
of Akt1 and/or -2 in cells overexpressing wild-type IGF-IR
(Fig. 2 A). Although several shRNA vectors targeting Akt3
were evaluated, none consistently down-regulated Akt3 ex-
pression. The down-regulation of Akt1 or -2 using shRNA vec-
tors was at least 75% (Fig. 2 A and Fig. S1) and confirmed to
be stable for at least 2 wks (not depicted).
Down-regulation of Akt1 or -2 had a significant impact on
the proliferation of IGF-IR cells in monolayer culture. Reduc-
tion of either Akt1 or -2 resulted in decreased cell numbers, al-
though the loss of Akt1 consistently induced a more significant
effect (Fig. 2 B). Interestingly, shRNA-induced down-regula-
tion of Akt1 or -2 also caused dramatic differences in the mor-
phology of MCF-10A cells in both monolayer and 3D cultures.
In monolayer cultures, down-regulation of Akt2 reverted the
spindle-shaped morphology induced by wild-type IGF-IR over-
expression (Fig. 2 C, top); in confluent cultures Akt2 down-
regulated cells assumed a tightly packed, cuboidal appearance,
which is characteristic of parental MCF-10A and normal epithe-
lial cells (Fig. 2 C, compare c with a and b). In contrast, Akt1
down-regulation exaggerated the spindle-shaped, fibroblastic
morphology, and many cells displayed ruffled surfaces (Fig. 2
C, d). IGF-IR cells that were dually expressing Akt1 and -2
shRNA vectors displayed a cuboidal morphology similar to the
parental MCF-10A cells (Fig. 2 C, e), suggesting that Akt2 is
required for the spindle-shaped phenotype induced by Akt1
down-regulation and indicating that the spindle morphology is
not a consequence of the more significant reduction in total Akt
caused by reduction of the dominant Akt1 isoform.
In 3D Matrigel/collagen (50:50) cultures (Fig. 2 C, middle
and bottom), Akt2 down-regulation suppressed the IGF-IR–
induced hyperproliferative phenotype, resulting in structures
that resembled parental MCF-10A acini, although slightly
larger (Fig. 2 C, compare h with g and f). We also examined the
effects of Akt2 down-regulation on IGF-IR–induced hyperpro-
liferation, by examining expression of Ki67, a marker of cy-
cling cells, and on luminal apoptosis by examining caspase-3
cleavage. IGF-IR structures exhibited significant Ki67 staining
Figure 2. Isoform-specific down-regulation
of Akt results in distinct phenotypes. (A) IGF-IR
cells were superinfected with shRNA vectors
targeting Akt1 and/or -2. Empty vectors (V)
were used as controls. Immunoblotting with
antibody against actin was used to confirm
equal loading. Cells in monolayer cultures
were lysed and immunoblotted with Akt iso-
form-specific antibodies. (B) IGF-IR cells super-
infected with empty vector, Akt1 shRNA, Akt2
shRNA, or both were grown in triplicate
monolayer cultures for the indicated days in
media containing EGF and IGF-I (100 ng/ml),
with initial seeding of 2.5   10
4 cells. Cells
were trypsinized, stained with Trypan blue,
and counted. A representative experiment of
three independent experiments is shown. Error
bars represent means   SD. (C) IGF-IR cells in
which either Akt1 and/or -2 were down-regu-
lated were cultured in monolayer (top) or 3D
Matrigel/collagen (50:50) cultures for 8 d
(middle and bottom). Monolayer cultures were
grown in the presence of EGF and IGF-I (100
ng/ml). 3D cultures were grown in the presence
of 5 ng/ml EGF and 100 ng/ml IGF-I. Bars:
(top and middle) 50  M; (bottom) 100  M. 
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at day 16, unlike parental MCF-10A cultures, which have ar-
rested proliferation by this time period (Debnath et al., 2002).
In contrast, Akt2–down-regulated IGF-IR structures underwent
proliferative arrest similar to that of parental MCF-10A acini,
as demonstrated by the absence of Ki67 staining at day 16.
(Fig. 3, bottom). IGF-IR 3D structures cultured in the presence
of IGF-I also exhibit filled lumen because of their failure to un-
dergo cavitation via apoptosis of centrally localized cells, a key
feature of morphogenesis of parental MCF-10A acini (Debnath
et al., 2002). Suppression of Akt2 expression restored lumen
formation and luminal apoptosis, with intense activated cas-
pase-3 staining in the presumptive luminal space (Fig. 3).
In contrast, Akt1 down-regulation dramatically disrupts
acinar morphogenesis, thus precluding evaluation of lumen for-
mation or growth arrest. Furthermore, Akt1 down-regulation in-
duced a dramatic neomorphic effect involving the production of
protrusive extensions that invaded the basement membrane gel
(Fig. 2 C, i). This effect resembles organotypic structures that
have undergone EMT. These protrusions were evident as early
as day three of 3D cultures. Finally, IGF-IR acini that dually ex-
press Akt1 and -2 shRNA vectors did not form protrusions and
their replicative potential in 3D cultures was significantly com-
promised, resulting in the formation of small, irregular struc-
tures that did not resemble normal acini (Fig. 2 C, j). Thus,
down-regulation of either Akt1 and/or -2 isoforms influences
IGF-I induced morphological changes in distinct ways.
 
Akt1 down-regulation enhances 
migration of IGF-IR–overexpressing cells 
and enhances expression of EMT markers
 
To establish whether Akt1 down-regulation also affects the
migratory behavior of IGF-IR cells, as well as their invasive
activity in basement membrane cultures, we examined cell
motility in transwell assays. Ligand stimulation of control or
IGF-IR cells did not stimulate migration in transwell assays.
(Fig. 4 A, top). However, down-regulation of Akt1 with either
shRNA sequence (sequence A or B) caused a dramatic en-
hancement of cell migration relative to IGF-IR cells superin-
fected with control empty vectors. In contrast, down-regulation
of Akt2 did not enhance migration of IGF-IR cells. The increase
in migration observed with Akt1 down-regulation occurred
under basal conditions, but was significantly enhanced by IGF-I
stimulation. The enhanced basal and IGF-I–stimulated migra-
tion induced by Akt1 down-regulation was impaired with con-
comitant Akt2 down-regulation (Fig. 4 A, bottom), suggesting
that Akt2 is required for this effect of Akt1 down-regulation.
To address whether the effect of Akt1 down-regulation is
because of more significant loss of this dominant Akt isoform,
we generated IGF-IR cells that overexpress wild-type Akt2,
such that Akt1 is no longer present in excess of Akt2. Akt1
down-regulation in these cells also resulted in enhanced migra-
tion (Fig. S2 A, available at http://www.jcb.org/cgi/content/
full/jcb.200505087/DC1), thus supporting the isoform specific-
ity of the effect on migration.
The enhanced migration observed with Akt1 down-regu-
lation was accompanied by changes in protein expression that
are consistent with EMT (Fig. 4 B). In EMT, the expression of
epithelial proteins (e.g., E-cadherin) is suppressed and the ex-
pression of mesenchymal genes (e.g., vimentin and N-cadherin)
is enhanced (for reviews see Grunert et al., 2003; Thiery,
2003). Ligand stimulation of IGF-IR cells resulted in mini-
mal changes in the expression of these proteins when com-
pared with parental MCF-10A cells, despite the morphological
changes. However, Akt1 down-regulation repressed E-cad-
herin expression and enhanced N-cadherin expression. Parental
MCF-10A cells express basal levels of vimentin; however,
Akt1 down-regulation consistently induced a small increase in
its expression in IGF-IR cells. In contrast, Akt2 down-regula-
tion in IGF-IR–overexpressing cells had no detectable effect on
E-cadherin levels. Interestingly, vimentin expression was sig-
nificantly decreased, even below the baseline observed with
parental MCF-10A cells. Collectively, these results suggest
that Akt1 down-regulation in IGF-IR cells promotes pheno-
typic changes associated with EMT, as demonstrated by alter-
ations in epithelial and mesenchymal protein expression and
migratory capacity. In contrast, Akt2 down-regulation does not
alter expression of E-cadherin or N-cadherin, but does reduce
expression of vimentin to levels lower than the basal levels
detected in control MCF-10A cells, suggesting that Akt2 ex-
pression may be necessary for vimentin expression.
 
ERK activation is enhanced by Akt1 
down-regulation
 
Hyperactivation of the ERK/MAP kinase pathway, via either
activation of Ras or a growth factor receptor, plays a coopera-
tive role in many models of EMT (for review see Grunert et
al., 2003). Akt1 overexpression has previously been reported
to suppress ERK activation (Rommel et al., 1999; Zimmer-
mann and Moelling, 1999). Therefore, we examined the effect
of down-regulating Akt1 or -2 on activation of ERK signaling.
Figure 3. Akt2-specific down-regulation inhibits IGF-IR–induced changes
in 3D cultures. IGF-IR cells expressing Akt2 shRNA vector were cultured in
3D Matrigel cultures for 8 or 16 d in the presence of EGF and IGF-I (100
ng/ml). Structures were stained with antibodies to cleaved caspase-3 or
Ki-67 (green),  6 integrin (red), and TOPRO (blue). Equatorial confocal
images are shown. Bars, 50  M. 
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Immunoblotting with antibody to activated ERK1/2 showed
that Akt1 down-regulation caused an activation of ERK in
nonstimulated cells and enhanced ERK activation under IGF-I–
stimulated conditions (Fig. 5 A). Enhanced ERK activation
was also observed with Akt1 down-regulation in cells overex-
pressing Akt2 (Fig. S2 B). In contrast, down-regulation of
Akt2 in IGF-IR cells had no effect on ERK1/2 activation.
Cells in which both Akt1 and -2 were down-regulated exhib-
ited enhanced ERK activation, comparable with that ob-
served with Akt1 down-regulation alone (Fig. 5 B).
To assess whether enhanced ERK activation was suffi-
cient to induce phenotypic alterations in IGF-IR cells similar
to those caused by Akt1 down-regulation, we overexpressed
an activated variant of MEK2 (MEKDD) in IGF-IR or Neo
cells (Fig. 6). Expression of MEKDD in IGF-I–stimulated
IGF-IR cells enhanced the spindle-shaped morphology of
these cells in monolayer cultures (Fig. 6 A). MEKDD overex-
pression also enhanced migration of both IGF-IR and Neo
control cells in the presence of IGF-I (Fig. 6 B). However, in
3D cultures, only cells expressing both ectopic IGF-IR and
MEKDD were capable of forming structures with invasive
protrusions that resembled those observed with Akt1 down-
regulation (Fig. 6 C). Despite their migratory capacity in tran-
swell assays, MEKDD-overexpressing parental MCF-10A
cells formed normal acinar structures. We have previously
shown that MEKDD cells produce EGF receptor ligands,
which could be responsible for the migration observed with
MEKDD cells (Debnath et al., 2003b).
The effect of MEKDD expression on epithelial markers
was also assessed. MEKDD expression alone was sufficient to
enhance expression of N-cadherin (Fig. 6 D). However, consis-
tent with the 3D assays, only coexpression of MEKDD in
ligand-stimulated IGF-IR, but not control MCF-10A, cells re-
sulted in significant repression of E-cadherin expression (Fig.
6 D). Thus, ERK hyperactivation, driven by activated MEK,
in ligand-stimulated, IGF-IR–overexpressing cells was suffi-
cient to phenocopy both the morphological alterations, loss of
Figure 4. Down-regulation of Akt1 in IGF-IR
cells induces migration and EMT. (A, top) The
motility of IGF-IR cells with isoform-specific
down-regulation of Akt was assessed using
transwell assays. Cells were starved overnight
in 2% serum in the absence of EGF and IGF.
Migration was assessed after 16–20 h in the
presence or absence of 100 ng/ml IGF-I. The
histogram displays the mean number of mi-
grated cells obtained by counting 10 separate
fields in three independent experiments.
(bottom) IGF-IR cells with down-regulation of
both Akt1 and -2 were starved and migration
in the presence or absence of IGF-I was as-
sessed. Shown is a representative experiment
displaying the mean number of migrated cells
in five separate fields. Error bars represent
means     SD. (B) IGF-IR cells infected with
empty vector control (V) or shRNA vectors
targeting Akt1 or -2 were grown in 2% horse
serum and 100 ng/ml IGF-I and lysed in NP-40
(for E- and N-cadherin) or RIPA buffer (Vi-
mentin). Lysates were immunoblotted with the
indicated antibodies.
Figure 5. ERK activation is enhanced by Akt1 down-regulation. (A) Neo
or IGF-IR cells with isoform-specific down-regulation of Akt were grown in
monolayer cultures, starved, and stimulated with 2% horse serum   100
ng/ml IGF-I in the absence of EGF. Lysates were immunoblotted with the
indicated antibodies. (B) IGF-IR cells overexpressing empty vector control,
Akt1 shRNA, or both Akt1 and -2 shRNA vectors were starved and stimu-
lated with 100 ng/ml IGF-I in the absence of EGF. Lysates were immuno-
blotted as indicated. 
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E-cadherin expression and increase in N-cadherin expression,
observed with Akt1 down-regulation.
 
Enhanced ERK activation is necessary 
for migration induced by Akt1 down-
regulation
 
To determine whether enhanced ERK activation is required for
the phenotypes induced by Akt1 down-regulation, we exam-
ined the effects of inhibiting MEK-induced ERK activation us-
ing UO126, a specific MEK inhibitor. Treatment with UO126
significantly inhibited migration of Akt1 down-regulated cells,
whereas treatment with a p38 inhibitor (SB 202190) or DMSO
vehicle control had no effect (Fig. 7 A). Furthermore, this in-
hibition was observed at low concentrations of UO126 (2
 
 
 
M), which reduced IGF-I–stimulated ERK activation in Akt1
down-regulated IGF-IR cells to the levels observed in IGF-IR
control cells (Fig. 7 B); thus, these effects are detectable at levels
of ERK inhibition that would not be expected to affect basal
cell functions.
The effect of MEK/ERK inhibition on epithelial and
mesenchymal protein expression was also examined (Fig. 7, C
and D). Interestingly, sustained treatment with UO126 over
3–5 d did not reverse the down-regulation of E-cadherin. Fur-
thermore, the enhancement in N-cadherin expression observed
with Akt1 down-regulation was also resistant to UO126 treat-
ment. These results suggest that although enhanced ERK ac-
tivity observed with Akt1 down-regulation is necessary and
sufficient for migration of IGF-IR cells, the effects on EMT
gene expression may be irreversible or that other pathways
may contribute to the sustained maintenance of EMT gene
expression changes.
 
Down-regulation of Akt1 enhances 
migration and ERK activation induced 
by EGF
 
The phenotypes observed with Akt1 down-regulation in IGF-IR
cells suggested that Akt1 has an inhibitory effect on IGF-I–trig-
gered migration and ERK activation. To determine whether
similar effects are observed when cells are stimulated by other
growth factor receptors, we examined migration and ERK acti-
vation in response to EGF stimulation (Fig. 8). Endogenous
levels of EGF receptor are sufficient to robustly induce these
activities upon EGF stimulation. The effects of Akt isoform
down-regulation was examined in the context of subsaturating
EGF concentrations. Akt1 down-regulation enhanced EGF-in-
duced ERK activation and migration. In contrast, Akt2 down-reg-
ulation inhibited EGF-stimulated transwell migration at all con-
centrations evaluated. This inhibition is more readily apparent as
EGF, in contrast to IGF-I, robustly induces migration. Thus, Akt1
down-regulation has similar effects on ERK activation and
migration when cells are stimulated by another growth factor.
Figure 6. Expression of constitutively active MEK in IGF-IR cells results in
invasive structures and repression of E-cadherin. (A) IGF-IR or Neo cells
overexpressing vector control or constitutively active MEK2 (MEKDD) were
grown in monolayer cultures containing EGF and IGF-I (100 ng/ml). Bar,
50  M. (B) Transwell migration assay and western analyses of IGF-IR or
Neo cells overexpressing MEKDD were performed. Cells were starved in
the absence of EGF for 24 h. Migration was assessed after 16–20 h in
media containing 2% horse serum and 100 ng/ml IGF-I. Lysates were im-
munoblotted as indicated. Error bars represent means   SD. (C) IGF-IR or
Neo cells overexpressing MEKDD were grown in 3D Matrigel/collagen
(50:50) cultures for 12 d. All cells were maintained in 2% horse serum,
EGF, and 100 ng/ml IGF-I. Phase-contrast images are shown. Bar, 50
 M. (D) IGF-IR or Neo cells overexpressing vector control (V) or MEKDD
were grown in monolayer cultures with 2% horse serum and 100 ng/ml
IGF-I. Cells were lysed in NP-40 lysis buffer and lysates were immunoblotted
with the indicated antibodies.
Figure 7. Inhibition of ERK signaling inhibits migration of Akt1 down-
regulated cells. (A) Migration of IGF-IR cells expressing Akt1 shRNA or
empty vector (V) control treated with DMSO, 2–10  M UO126, or 10
 M SB 202190 was assessed using transwell migration assay. Cells were
starved in the absence of EGF. Migration was assessed after 16–20 h in
media containing 2% horse serum, 100 ng/ml IGF-I, and DMSO or inhib-
itor. The histogram displays the mean percentage migration relative to
Akt1 down-regulated IGF-IR cells treated with DMSO within the same ex-
periment. The mean values were derived from three independent experi-
ments. Error bars represent means   SD. (B) Akt1 down-regulated IGF-IR
cells were grown in 2% serum, 100 ng/ml IGF-I, and DMSO, 2–10  M
UO126, or SB 202190 for 72 h, with the inhibitor replaced after 48 h.
Lysates were immunoblotted as indicated. (C) IGF-IR cells expressing Akt1
or empty vector shRNA were cultured in 2% serum, IGF-I, and DMSO or
2–10  M UO126 for 72 h, lysed in NP-40 lysis buffer, and immunoblot-
ted with antibodies against E-cadherin. (D) IGF-IR cells expressing Akt1 or
empty vector shRNA and cultured in 2% serum, IGF-I, and DMSO or 2–10
 M UO126 for 72 h were lysed in RIPA lysis buffer and immunoblotted
with the indicated antibodies. 
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Overexpression of Akt1 suppresses 
EGF-dependent migration and ERK 
activation
 
To more directly assess the potential inhibitory effect of Akt1
on growth factor–induced migration and ERK activation,
MCF-10A cells overexpressing wild-type or HA-tagged Akt1
or -2 were generated by retroviral infection. Comparable levels
of overexpression were confirmed using antibodies that recog-
nize the HA tag or all Akt isoforms (panAkt; Fig. 9 A). Because
ligand-stimulated IGF-IR cells are not motile, we examined the
effects of Akt1 or -2 overexpression on parental MCF-10A
cells treated with EGF, which induces robust migration and
strong activation of ERK. Comparable total levels of activated,
phosphorylated Akt were induced after EGF stimulation
(Fig. 9 A). Phosphorylation of glycogen synthase kinase-3
(GSK3)
 
 
 
, a known Akt substrate (Brazil et al., 2004), was also
comparable in cells overexpressing Akt1 or -2, further confirm-
ing equivalent levels of Akt activity. In comparison to control
MCF-10A cells, wild-type Akt1-overexpressing cells exhibited
decreased migration in response to EGF stimulation (Fig. 9 B).
These results are consistent with previous studies in which
overexpression of wild-type or activated Akt1 in breast cancer
cell lines slightly decreased migration and invasion (Shaw et
al., 1997; Arboleda et al., 2003). In contrast, overexpression of
wild-type Akt2 did not affect EGF-induced migration.
The effect of Akt1 overexpression on EGF-stimulated
ERK activation was also examined. Lysates of EGF-stimulated
vector control or Akt1-overexpressing MCF-10A cells were
immunoblotted with an antibody against activated ERK1/2.
The level of activated ERK detected in lysates of Akt1-overex-
pressing cells was decreased when compared with parental
MCF-10A cells (Fig. 9 C). These results are consistent with a
negative, inhibitory effect of Akt1 on migration and ERK activa-
tion. In contrast, overexpression of wild-type Akt2 in MCF-10A
did not affect ERK activation induced by EGF. These results in-
dicate that Akt1 may exert an isoform-specific suppressive effect
on growth factor–stimulated ERK activity.
 
Discussion
 
Akt is activated downstream of the growth factor receptors and
oncogenes implicated in human cancer and plays a critical role
in normal development, as well as in tumor pathogenesis, via
effects on metabolism, survival, and proliferation. The role of
Akt in cell migration and metastases is less clear because of
conflicting studies suggesting either positive or negative regu-
latory roles (Shaw et al., 1997; Park et al., 2001). Previous
studies have largely relied on overexpression strategies in cancer
cell lines or pharmacological inhibitors of PI 3-kinase activity,
which would inhibit activity of all Akt isoforms. We describe
studies that reveal isoform-specific roles for endogenous Akt1
and -2 in both positive and negative regulation of processes
Figure 8. Down-regulation of Akt1 enhances EGF-stimulated migration
and ERK activation. (A) MCF-10A cells overexpressing empty vector or
Akt1 or -2 shRNA vectors were generated. Isoform-specific down-regulation
was confirmed by Western analysis and migration in response to EGF
stimulation was assessed. Before plating in transwell assays, cells were
starved overnight in the absence of EGF. Cells were stimulated with EGF
at the indicated concentrations and migration was assessed. The histo-
gram displays a representative experiment with mean values obtained by
counting 10 independent fields. Error bars represent means   SD. (B)
MCF-10A cells overexpressing empty vector control or Akt1 or -2 shRNA
vectors were starved in the absence of EGF. Cells were stimulated with the
indicated concentrations of EGF, lysed, and immunoblotted with the indi-
cated antibodies.
Figure 9. Overexpression of Akt1 suppresses EGF-stimulated migration
and ERK activation. (A) MCF-10A cells overexpressing HA-tagged wild-
type Akt1 or -2 were generated. (top) Levels of overexpression were con-
firmed using antibodies against the HA tag or a panAkt antibody that
recognizes all isoforms. (bottom) Levels of activated, phosphorylated Akt
and phosphorylated GSK3  were assessed after EGF stimulation. (B)
Migration of MCF-10A cells overexpressing vector control or wild-type
HA-tagged  Akt1 or -2 was assessed by transwell assay. Cells were
starved in the absence of EGF for 24 h. Migration was assessed after 16–
20 h in media with 2% horse serum   5 ng/ml EGF. A representative ex-
periment is shown with mean values obtained by counting 10 separate
fields. Error bars represent means   SD. (C) MCF-10A cells overexpressing
vector control or wild-type Akt1 or -2 were starved for 24 h and stimulated
with media containing 2% horse serum   5 ng/ml EGF. Cells were lysed
and immunoblotted with the indicated antibodies. 
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downstream of growth factor receptors and provide insights
into mechanisms that may be partly responsible for those con-
flicting conclusions. In addition, we provide evidence for the
importance of Akt1 in a cross-regulatory control circuit be-
tween the PI 3-kinase and ERK signaling pathways, two of the
major pathways that regulate diverse cellular activities. Differ-
ential regulation of signaling pathways by Akt isoforms may
critically contribute to their distinct roles in normal develop-
ment and disease pathogenesis.
The 3D culture system used in this study provides an in
vitro model to investigate phenotypic effects that resemble
events that take place during breast cancer initiation and pro-
gression, such as escape from proliferative suppression, filling
of the hollow acinar luminal space, and induction of protrusive,
invasive behavior (Debnath et al., 2003a). We demonstrate that
enhanced IGF-I signaling leads to the formation of constitu-
tively proliferating structures with low apoptotic activity and
filled lumen. These structures share features with noninvasive
breast carcinoma in situ, including maintenance of basement
membrane architecture, absence of a hollow lumen, and hyper-
proliferation. These results extend our understanding of the
phenotypic effects of IGF-IR hyperstimulation derived from
previous studies in monolayer cultures.
The use of shRNA vectors has made it feasible to investi-
gate cellular pathways required for the distinct IGF-IR–induced
phenotypic effects in our model and revealed interesting, isoform-
specific functions of Akt. Akt2 down-regulation caused a near
complete inhibition of the IGF-IR phenotype in 3D cultures;
the structures failed to escape proliferation arrest, to suppress
apoptosis of centrally localized cells, and to fill the luminal
space. These results indicate that either reduction of Akt2 spe-
cifically, or reduction in total Akt levels, suppresses all of the
phenotypic effects observed in 3D culture. In contrast, Akt1
down-regulation resulted in a surprising conversion of IGF-IR
structures from large, misshapen, solid masses to invasive
structures that displayed features associated with EMT (fibro-
blast-like morphology, enhanced migration, loss of epithelial
markers, and acquisition of mesenchymal gene expression).
These results are consistent with an inhibitory role for endoge-
nous Akt1 in these processes.
Our data suggest that one target of the inhibitory activ-
ity of Akt1 is the ERK signaling pathway, as specific down-
regulation of Akt1 enhanced ERK activation both in response
to IGF-I or EGF stimulation. These data are consistent with
previous studies in which overexpression of activated Akt1
decreased ERK activity (Rommel et al., 1999; Zimmermann
and Moelling, 1999). Our studies highlight the isoform-spe-
cific nature of this effect and establish a role for endogenous
Akt1 protein in modulating ERK under conditions of growth
factor stimulation. The ability of endogenous Akt to cross-
regulate Ras/Raf/MEK/ERK signaling may be conserved
across species, as Akt down-regulation in 
 
Drosophila mela-
nogaster
 
, which express only one isoform, enhances insulin-
stimulated ERK activation (Freedman, A., and N. Perrimon,
personal communication).
Several lines of evidence suggest that inhibition of ERK
and migration is specific for Akt1 and unlikely because of the
different degrees of residual Akt activity after down-regulation.
First, comparable degrees of overexpression of Akt1, but not
Akt2, inhibits ERK activation and migration stimulated by
EGF. Second, reduction of Akt2 in the background of Akt1
shRNA expression does not enhance ERK activation or migra-
tion. Dual down-regulation of Akt2 suppresses enhanced mi-
gration in cells overexpressing Akt1 shRNA vectors. Finally,
overexpression of Akt2 to levels comparable or greater than
Akt1 does not prevent the effects of Akt1 down-regulation,
thus supporting an isoform-specific effect of Akt1 that occurs
regardless of total levels of residual Akt.
Akt1-mediated inhibition of the ERK pathway could oc-
cur at multiple levels. Constitutively active Akt1 is able to
phosphorylate a residue (Ser259) of Raf, which mediates bind-
ing to 14-3-3 proteins, causing inhibition of Raf activity (Zim-
mermann and Moelling, 1999). In preliminary studies, we have
not observed significant changes in Ser259 phosphorylation of
Raf with Akt1 down-regulation (unpublished data). PI 3/Akt
kinase signaling has also been shown to regulate ERK up-
stream of Raf at the level of IRS-1–Grb2 complex formation
(Choi and Sung, 2004). Furthermore, constitutively active Akt1
has been reported to suppress ERK activity downstream of Raf
and MEK and independent of ERK phosphorylation (Galetic et
al., 2003). Thus, there may be multiple levels of ERK regula-
tion and studies are underway to delineate these mechanisms.
The importance of enhanced ERK activation in migration
and induction of EMT is supported by studies in which ERK
activity was found to be critically involved in EMT induced by
other stimuli, such as Ras/TGF
 
 
 
 (Janda et al., 2002), EGF/
TGF
 
 
 
 (Grande et al., 2002), and HGF/ErbB2 (Khoury et al.,
2005). Pharmacological inhibition of ERK signaling has been
shown to decrease invasion or inhibit specific biochemical
changes consistent with EMT induced by these stimuli. In our
study, enhancement of ERK activation, via a constitutively ac-
tive MEK2, appears to be sufficient to induce migration, con-
version to an invasive phenotype in 3D cultures, repression of
E-cadherin, and induction of N-cadherin expression in collabo-
ration with IGF-I hyperstimulation. Furthermore, the enhanced
migration induced by Akt1 down-regulation is sensitive to
pharmacological inhibition of MEK/ERK signaling.
Interestingly, however, ERK inhibition did not restore
expression of epithelial markers or significantly down-regulate
mesenchymal markers in Akt1 down-regulated cells that had
undergone EMT. These results are consistent with previous
ones showing that, although pretreatment or concomitant treat-
ment with a pharmacological MEK inhibitor is able to prevent
invasion or the development of EMT (Grande et al., 2002;
Janda et al., 2002; Khoury et al., 2005), treatment after the es-
tablishment of EMT did not (Khoury et al., 2005). The failure
to completely reverse EMT may be caused by irreversible
changes induced by enhanced ERK activation or to ERK-inde-
pendent pathways that are sufficient to maintain the mesen-
chymal phenotype induced by Akt1 down-regulation. GSK3
 
 
 
signaling has previously been implicated in E-cadherin sup-
pression (Zhou et al., 2004); however, we have not observed
significant changes in GSK3
 
 
 
 phosphorylation after Akt1
down-regulation (unpublished data). Induction of EMT by both 
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Ras and FosER has been reported to induce an autocrine TGF
 
 
 
loop that stabilizes the mesenchymal phenotype (Gotzmann et
al., 2002; Janda et al., 2002; Eger et al., 2004). EMT induced
by Akt1 down-regulation may lead to the production of a simi-
lar stabilizing soluble factor. Thus, combined inhibition of
multiple signaling pathways may be required for full reversion
of EMT induced by Akt1 down-regulation.
Akt2 may play a role in growth factor–stimulated migra-
tion and invasion that is distinct, if not contrasting, to that of
Akt1. This is based on our observations that Akt2 down-regu-
lation suppressed migration stimulated by EGF or Akt1
down-regulation, and Akt2 down-regulation reverted the spin-
dle-shaped morphological changes induced by Akt1 down-
regulation. These observations are consistent with previous
studies that reported that Akt2 overexpression in breast can-
cer cell lines enhanced their invasive potential and inhibition of
Akt2 (via overexpression of dominant-negative constructs) sup-
pressed invasion and metastases triggered by ErbB2 overexpres-
sion (Arboleda et al., 2003). Although differential localization
and regulation of adhesion molecules (e.g., 
 
 
 
1 integrin) was im-
plicated in these Akt2 isoform-specific effects, additional studies
to examine endogenous Akt2 functions are ongoing.
The present studies do not allow us to establish whether
Akt2 preferentially regulates the antiapoptotic activities of Akt
because the loss of Akt1 disrupted acinar morphogenesis to
such an extent that analysis of apoptosis in the presumptive lu-
minal space could not be evaluated. For similar reasons, we
were unable to examine escape from proliferative arrest in
Akt1 down-regulated 3D acini. However, we did observe that
proliferation of IGF-I–stimulated cells in monolayer cultures
was significantly impaired after down-regulation of either Akt1
or -2, indicating that both proteins contribute to IGF-I–stimu-
lated proliferation. Several targets of Akt family proteins have
been shown to regulate cell proliferation and apoptosis through
effects on the expression or activity of several proteins includ-
ing cyclin D, cyclin-CDK inhibitors, mTOR, and proapoptotic
proteins Bad and FOXO transcription factors (for review see
Brazil et al., 2004). None of the Akt substrates that regulate
these proteins have been shown to be specifically phosphorylated
by Akt1 or -2. In our preliminary studies, IGF-IR–stimulated
phosphorylation of GSK3, FOXO3a, and S6 is not significantly
affected by Akt1 or -2 suppression (unpublished data). Previous
studies in adipocytes indicated that isoform-specific loss of
Akt2 has a more substantial impact on insulin-stimulated glu-
cose uptake than does loss of Akt1 (Bae et al., 2003; Jiang et
al., 2003; Katome et al., 2003). Because glucose and other nu-
trient transporters regulate metabolic processes that affect cell
proliferation, effects of Akt2 down-regulation on this pathway
may contribute to the reduction in cell proliferation and survival.
The precise contributions of Akt1 and -2 to IGF-IR–induced
proliferation and antiapoptotic activity require further investi-
gation. In addition, it will be important to examine whether
changes in the level of expression of Akt isoforms during mor-
phogenesis contribute in part to the effects of Akt1 and -2
down-regulation in 3D cultures.
The specific mechanisms responsible for the distinct
roles of Akt1 and -2 are not known; however, there are a few
explanations extrapolated from previously published studies.
Differential subcellular localization or binding partners may
determine isoform-specific functions. Akt2 expression was re-
ported to be most prominent in regions of cell–matrix contact
(Arboleda et al., 2003). Preferential localization of Akt2 to ar-
eas of cell–matrix contact may therefore enable interactions
with molecules required for motility and invasion. Differential
localization may result from distinct protein-binding interac-
tions. Although the Akt isoforms exhibit significant sequence
homology and possess similar domain structure, the greatest
variation is located within the phosphoinositide-binding PH
domain. Indeed, the L-jun NH
 
2
 
-terminal kinase scaffold pro-
teins POSH and L-jun NH
 
2
 
-terminal kinase interacting protein 1
interact selectively with the PH domains of Akt2 and -1, re-
spectively (Kim et al., 2002; Figueroa et al., 2003). Chimeric
variants of Akt1 and -2 may be useful in establishing which do-
mains of each protein are required for the regulation of ERK
activation and cell migration.
The balance between Akt isoform activation downstream
of IGF-IR and other growth factor receptors may influence the
invasive or metastatic potential of tumors or tumor cell lines.
The relative abundance or activation of Akt isoforms may be
dynamic and change depending on different cellular contexts.
Whether migration or invasion is stimulated may depend on the
extent to which a particular agonist activates Akt1 and the extent
to which ERK is influenced by Akt1. For example, in tumor
cells carrying mutations in Ras or Raf, which activate ERK
constitutively, IGF-I may promote cell migration and invasion.
Likewise, the ability of wild-type or constitutively activated
Akt1 to modulate migration and invasion may depend on
whether migration is ERK dependent. The ability of Akt to
cross-regulate Ras/Raf/MEK/ERK signaling may also be influ-
enced by mediators that are contextually expressed; e.g., differ-
entiation status in myocytes correlated with the ability to form
inhibitory Akt–Raf complexes (Rommel et al., 1999).
The suppressive effects of Akt1 on invasive activity re-
ported previously are consistent with evidence that coexpression
of activated Akt1 with oncogenic ErbB2 in mouse mammary
epithelial cells decreases the metastatic activity of oncogenic
ErbB2 (Hutchinson et al., 2004). However, further studies are
required to investigate the precise mechanisms for this decrease.
Interestingly, activated Akt1 can rescue the tumor-inducing
potential of a mutant form of the polyomavirus middle T antigen
that lacks a PI 3-kinase binding site, but does not rescue its in-
vasive activity (Hutchinson et al., 2001). This could result from
Akt1-mediated suppression of ERK activation or from a critical
requirement for Akt2 or other downstream PI 3-kinase targets.
Acute, inducible knockout of Akt isoforms in transgenic tumor
models should be informative in establishing the role of specific
Akt isoforms in tumorigenesis in vivo.
Efforts are underway to develop pan- or isoform-specific
Akt inhibitors as cancer therapeutics (for review see Barnett et
al., 2005). Akt2 is amplified in breast and ovarian tumors and,
more recently, mutations thought to be activating have been de-
tected in colon cancer (Bellacosa et al., 1995; Parsons et al.,
2005). Thus, Akt2 may be a particularly attractive candidate for
therapeutic inhibition. The consequences of isoform-specific 
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inhibition will need to be carefully evaluated in different cellular
contexts, especially as there may be unanticipated, differential
effects on other signaling pathways, as observed in our studies.
The effect of isoform-specific inhibition on different aspects of
the tumorigenic phenotype may also vary. Although Akt1 and -2
both contribute to proliferation, isoform-specific pharmacological
inhibition may have a differential impact on migration and in-
vasion. Understanding these differences will be key to the devel-
opment of improved targeted therapeutic strategies.
 
Materials and methods
 
Cell culture 
 
MCF-10A cells were obtained from American Type Culture Collection and
cultured, as previously described in Debnath et al. (2003a), in DME/F12
(Invitrogen) supplemented with 5% horse serum, 20 ng/ml EGF, 10 
 
 
 
g/ml
insulin or 100 ng/ml IGF-I (R&D Systems), 0.5 
 
 
 
g/ml hydrocortisone, 100
ng/ml cholera toxin, 50 U/ml penicillin, and 50 mg/ml streptomycin.
 
Reagents
 
Antibodies against phosphorylated IGF-IR/insulin receptor, phosphory-
lated Akt (Ser 473), phosphorylated MEK (Ser217/221), phosphorylated
GSK3
 
 
 
 (Ser9), and GSK3
 
 
 
 were purchased from Cell Signaling Technol-
ogy. Phosphorylated ERK1/2 (Threonine185/Tyrosine187) was obtained
from Biosource International. IGF-IR 
 
 
 
 chain, ERK2, MEK, and actin were
purchased from Santa Cruz Biotechnology, Inc. Akt1 was purchased from
Upstate Biotechnology; Akt3 and panAkt antibody were obtained from
R&D Systems; and E-cadherin, N-cadherin, and vimentin were purchased
from BD Biosciences. The Akt2-specific antibody and purified Akt1, -2,
and -3 were gifts of M. Birnbaum (University of Pennsylvania, Philadel-
phia, PA). MEK inhibitor UO126 and p38 inhibitor SB 202190 were pur-
chased from Calbiochem.
 
Retroviral/lentiviral DNA vectors and viru2s production
 
The pMSCV-Neo–based retroviral vectors encoding wild-type human IGF-
IR complementary DNA and IGF-IR variants were gifts of R. Baserga
(Thomas Jefferson University, Philadelphia, PA). pBABE-MEK2DD was a gift
of S. Meloche (Institut Recherches Clinique de Montreal, Montreal, Quebec,
Canada). The pLNCX-based retroviral vector encoding wild-type HA-
tagged Akt1 was generated from a construct obtained from P. Tsichlis
(New England Medical Center-Tufts, Boston, MA). pBABE-puro–encoding
wild-type HA-tagged human Akt2 was generated from a construct obtained
from J. Cheng (University of South Florida, Tampa, FL). VSV-pseudotyped
vectors were produced by transfection of the VSV-GPG producer cell line
(a gift from R. Mulligan, Children’s Hospital, Boston, MA; Ory et al.,
1996) with 10 
 
 
 
g DNA using Lipofectamine 2000 (Invitrogen). Retrovirus-
containing supernatants were collected at days 5–7 after transfection and
were stored at 
 
 
 
80
 
 
 
C.
Retroviral (pMKO.1puro) or lentiviral (pLKO.1puro) vectors encod-
ing hairpin RNA sequences were used to down-regulate specific Akt iso-
forms. The hairpin sequences used for Akt1 were as follows: Akt1(A),
forward, 5
 
 
 
-CCGGTGCTGCTTCCTCCTCAAGAATGTTCAAGAGACAT-
TCTTGAGGAGGAAGTAGCTTTTTGGAAG-3
 
 
 
; reverse, 5
 
 
 
-AATTCTTCC-
AAAAAGCTACTTCCTCCTCAAGAATGTCTCTTGAACATTCTTGAGGAG-
GAAGCAGCA-3
 
 
 
; Akt1(B; a gift of W. Hahn, Dana-Farber Cancer Insti-
tute, Boston, MA), forward, 5
 
 
 
-CCGGGAGTTTGAGTACCTGAAGCT-
CCTCGAGGAGCTTCAGGTACTCAAACTCTTTTTG-3
 
 
 
; reverse, 5
 
 
 
-AAT-
TCAAAAAGAGTTTGAGTACCTGAAGCTCCTCGAGGAGCTTCAGGTAC-
TCAAACTC-3
 
 
 
. The hairpin sequences used for Akt2 were as follows:
Akt2 (A), forward, 5
 
 
 
-CCGGTGCGTGGTGGATACATCAAGACTTCA-
AGAGAGTCTTGATGTATTCACCACGCTTTTTGGAAG-3
 
 
 
; reverse, 5
 
 
 
-
AATTCTTCCAAAAAGCGTGGTGAATACATCAAGACTCTCTTGAAGTCTTG-
ATGTATCCACCACGCA-3
 
 
 
; Akt2(B), forward, 5
 
 
 
-CCGGTGAGGTGTTTG-
TCATCAAAGAATTCAAGAGATTCTTTGATGACAGACACCTCTTTTTGG-
AAG-3
 
 
 
; reverse, 5
 
 -AATTCTTCCAAAAAGAGGTGTCTGTCATCAAAG-
AATCTCTTGAATTCTTTGATGACAAACACCTCA-3 .
VSVG-pseudotyped retroviral or lentiviral vectors were generated
by the cotransfection of GP-2 (BD Biosciences) or 293-T packaging cells.
Generation of MCF-10A cell lines
MCF-10A cells (5   10
5 cells) were infected with the retroviral viruses,
and stable populations were chosen by selection with 2  g/ml puromycin
or 300  g/ml G418 (Sigma-Aldrich). Hairpin RNA–encoding retroviruses
and lentiviruses were used to superinfect IGF-IR–overexpressing MCF-10A
cells, and stable populations were obtained by dual selection with 2  g/ml
puromycin and 300  g/ml G418.
3D cultures
3D Matrigel (BD Biosciences) morphogenesis assays were performed as
previously described (Debnath et al., 2003a). Acini were cultured in as-
say media (2% horse serum, 5 ng/ml EGF, 0.5  g/ml hydrocortisone,
100 ng/ml cholera toxin, 50 U/ml penicillin, and 50 mg/ml streptomy-
cin   100 ng/ml IGF-I). Cultures were re-fed every 4 d. For collagen/Matri-
gel assays, a 50:50 mixture of growth factor–reduced Matrigel and bovine
dermal collagen I (Vitrogen Cohesion Technologies) was used as the un-
derlay. Before mixing, collagen I was neutralized as previously described
(Seton-Rogers et al., 2004).
Phase-contrast microscopy
Cells grown in monolayer cultures, as well as 3D acinar structures, were
visualized at 20 C using a microscope (model TE300; Nikon) equipped
with a camera (model MTI CCD-300T-RC; Dage), using a 4 , 0.13 NA,
or 10 , 0.3 NA, objective. Images were acquired using IP Lab Spectrum
software (BD Biosciences), converted to TIFF images, and arranged using
Photoshop 7.0 (Adobe).
Immunofluorescence analyses and confocal microscopy
Acinar structures were fixed in 2% formalin (Sigma-Aldrich) at room tem-
perature for 20 min and permeabilized in 0.5% Triton X-100 in PBS for
10 min at 4 C. Immunostaining of acinar structures was performed as pre-
viously described (Debnath et al., 2002, 2003a) and imaged at 20 C.
Confocal analyses were performed using a microscope (model TE2000;
Nikon) with the C1plus confocal microscope system equipped with krypton-
argon (488 line) and HeNe (543 and 633 lines) lasers (Nikon). Structures
were analyzed with a 40 , 1.3 NA, objective, and images were ac-
quired using C1 confocal software (Nikon). For each time point, the im-
ages presented are representative of four or more independent experi-
ments.  All images were converted to TIFF format and arranged using
Photoshop 7.0 (Adobe).
Western blot analysis
Cells were lysed in NP-40 lysis buffer (1% NP-40, 50 mM Tris, pH 7.6,
and 150 mM NaCl) or RIPA lysis buffer (1% Triton X-100, 1% NaDOC,
0.1% SDS, 20 mM Tris, pH 7.5, 150 mM NaCl, and 1 mM EDTA) supple-
mented with protease and phosphatase inhibitors (1  g/ml leupeptin, 1
 g/ml aprotinin, 1  g/ml pepstatin, 10  g/ml PMSF, 1 mM NaVO4,
and 1 mM NaF) for 30 min at 4 C. Lysates were clarified by centrifuga-
tion and supernatants were collected. Proteins were resolved by 8–10%
SDS-PAGE and immunoblotted using standard techniques.
Transwell migration assay
MCF-10A cells were starved overnight in assay media containing no EGF
and only 2% horse serum   100 ng/ml IGF-I. The cells were trypsinized
and 10
5 cells were added to the top chambers of 24-well transwell plates
(8  m pore size; BD Biosciences), and assay media (  IGF-I) was added
to the bottom chambers. For assays examining migration in the presence
of subsaturating concentrations of EGF, EGF was added after overnight
starvation. For assays using pharmacological inhibitors, the inhibitors
were added to the media at the initiation of the assay. After overnight in-
cubation, the nonmotile cells at the top of the filter were removed and the
motile cells at the bottom of the filter were fixed with 70% ethanol and
stained with 5  g/ml DAPI to visualize nuclei. The number of migrating
cells in each chamber was quantified by counting five fields under 20 
magnification. Each condition was performed in duplicate and the aver-
age number of cells per field is represented. Experiments were repeated a
minimum of three times.
Online supplemental material
Fig. S1 shows the relative levels of expression of Akt1, -2, and -3 in
MCF-10A cells, as well as the levels of down-regulation achieved with the
isoform-specific shRNA vectors used in the study. Fig. S2 shows enhance-
ment in migration and ERK activation observed with Akt1 down-regulation
in IGF-IR cells overexpressing Akt2. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200505087/DC1.
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